Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02628379 · ClinicalTrials.gov registry record
Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary
A clinical trial of Neoplasms, Unknown Primary and CUP, sponsored by Foundation Medicine.
- Completed
- Registry status
- 125
- Enrollment target
- 1
- Study location
NCT02628379: Completed study of Neoplasms, Unknown Primary and CUP, sponsored by Foundation Medicine.
NCT02628379 is a study of Neoplasms, Unknown Primary and CUP that has completed, run by Foundation Medicine. The registered enrollment target is 125 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02628379, a study of Neoplasms, Unknown Primary and CUP, has completed, sponsored by Foundation Medicine.
- COMPLETED
- Registry status
- 125 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of the current study is to determine whether Foundation Medicine's next generation sequencing assay, called FoundationOne, will provide information that allows physicians to make treatment decisions using targeted therapies in clinical trials or FDA approved therapies, including "off-label" agents, that result in superior OS compared to historical outcomes for standard CUP therapy.
Conditions Studied
Study Locations (1)
Massachusetts
- Foundation Medicine, Inc - Cambridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2015-05 |
| Est. Completion | 2017-03 |
What the finished NCT02628379 record still lists
NCT02628379 is an observational study that tracks outcomes without assigning an intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap.
The record links to 6 conditions, with Neoplasms, Unknown Primary appearing as the primary indexed condition, and to 0 interventions.
NCT02628379 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02628379 about?
NCT02628379 is a clinical study titled "Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary". The goal of the current study is to determine whether Foundation Medicine's next generation sequencing assay, called FoundationOne, will provide information that allows physicians to make treatment decisions using targeted therapies in clinical trials or FDA approved therapies, including "off-label"...
What is the current status of trial NCT02628379?
This trial is currently completed. The enrollment target is 125 participants. The study started on 2015-05. Estimated completion is 2017-03.
What conditions does trial NCT02628379 study?
This clinical trial studies the following conditions: Neoplasms, Unknown Primary, CUP, Metastatic Disease, Poorly Differentiated Adenocarcinoma, Poorly Differentiated Carcinoma.
Who is sponsoring clinical trial NCT02628379?
This trial is sponsored by Foundation Medicine, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02628379 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms, Unknown Primary
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia